Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Colorcon
Boehringer Ingelheim
Baxter
Teva
US Department of Justice
Farmers Insurance
Cipla
Mallinckrodt
AstraZeneca

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,469,030

« Back to Dashboard

Which drugs does patent 6,469,030 protect, and when does it expire?

Patent 6,469,030 protects ENTEREG and is included in one NDA.

This patent has seventeen patent family members in fourteen countries.
Summary for Patent: 6,469,030
Title: Methods for the treatment and prevention of ileus
Abstract:Methods for the treatment and/or prevention of ileus are disclosed. The methods comprise administering to a patient an effective amount of a peripheral mu opioid antagonist compound. Preferred compounds for use in the methods include piperidine-N-alkylcarboxylates.
Inventor(s): Farrar; John J. (Chester Springs, PA), Schied; Peter J. (Southampton, PA), Schmidt; William K. (Newark, DE), Carpenter; Randall L. (Waban, MA)
Assignee: Adolor Corporation (Exton, PA)
Application Number:09/725,708
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,469,030

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe A METHOD OF TREATING OR PREVENTING ILEUS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,469,030

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,696,220 Methods for the treatment or inhibition of ileus ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,469,030

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 432076 ➤ Subscribe
Australia 2005203041 ➤ Subscribe
Australia 3970501 ➤ Subscribe
Australia 780738 ➤ Subscribe
Canada 2393141 ➤ Subscribe
Cyprus 1109264 ➤ Subscribe
Germany 60042282 ➤ Subscribe
Denmark 1244448 ➤ Subscribe
European Patent Office 1244448 ➤ Subscribe
Spain 2329004 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Covington
AstraZeneca
QuintilesIMS
Julphar
Cipla
Cantor Fitzgerald
Federal Trade Commission
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot